December 11, 2024 7:58am
Is the sector’s share pricing at the mercy of or free of inflation-oriented releases?
Pre-open Indications: 1 Sell into Strength 3 Negative and 2 Positive Indications
NOT much has changed, as I have written, “uncle algo and his trading dwarfs” determine the heights or lows of share pricing”
November’s consumer price index, which tracks a basket of goods and services, was in line with expectations. The reading showed a 0.3% rise from October and 2.7% increase from a year ago. Excluding volatile food and energy prices, core CPI was projected to increase 0.3% on the month and 3.3% from 12 months earlier.
Never leave an investor uninform
Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.
My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today!
Tuesday’s night’s … RegMed Investors (RMi) Closing Bell: sector share pricing circles the drain … https://www.regmedinvestors.com/articles/13729
Wednesday Update: The pre-open Dow futures are UP +0.09% or (+35 points), the S&P futures are UP +0.26% or (+15 points) and the Nasdaq futures are UP +0.38% or (+85 points)
- Stock futures are up/positive on Wednesday, December 11, 2024,
- European markets were mixed,
- Asia-Pacific markets closed mixed.
Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies
Tuesday night’s action follows a losing day, marking the 2nd straight down day for the S&P 500 and Nasdaq and 4th negative session in a row for the Dow.
- This week so far, 2 negative closes, Tuesday and Monday
Economic Data Docket: Consumer Price Index, month-over-month, November (+0.3% expected, +0.2% prior); Core CPI, month-over-month, November (+0.3% expected, +0.3% previously); CPI, year-over-year, November (+2.7% expected, +2.6% previously); Core CPI, year-over-year, November (+3.3% expected, +3.3% previously); Real average hourly earnings, year-over-year, November (+1.4% previously) and MBA Mortgage Applications, week ending Dec. 6 (+2.8% prior);
Q4/24: December = 4 negative and 2 positive closes
- November 10 negative and 9 positive closes
- October: 8 positive and 15 negative closes
Companies in my headlights – It’s your decision; I provide ideas and context
I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.
A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.
Sell into Strength Indications:
Tuesday, Monday, Friday, Thursday and last Wednesday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)
Beam Therapeutics (BEAM) closed up +$2.69 after Monday’s +$0.81, Friday’s +$1.39, Thursday’s -$0.70 and last Wednesday’s +$0.04 following the previous Tuesday’s -$2.32 and Monday’s +$0.92 with a positive +$0.80 or +2.65% pre-open.
Negative Indications:
Tuesday, Monday, Friday, Thursday and last Wednesday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)
Ionis Pharmaceuticals (IONS) closed down -$0.32 after Monday’s +$0.47 and Friday’s $1.36 with a negative -$0.78 or -2.04% aftermarket
uniQure NV (QURE) closed up +$8.01 after Monday’s -$0.1 with a negative -$0.29 or -1.90% aftermarket,
Vericel (VCEL) closed up +$1.20 after Monday’s -$0.01, Friday’s-$0.15 and Thursday’s -$1.63 with a negative -$1.56 or +2.71% aftermarket
Positive indications:
Tuesday, Monday, Friday, Thursday and Wednesday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)
Moderna (MRNA) closed down -$4.14 after Monday’s +$1.21 with a positive +$0.11 or +0.26% pre-open
Voyager Therapeutics (VYGR) closed down -$0.18 after Monday’s -$0.08 with a positive +$0.12 or +1.94% aftermarket
The BOTTOM LINE: We have been subject to momentum reversals …
As I am STILL suspicious of the sector’s “froth” heading into this week as it runs while trend-chasing traders will turn-on the sector’s upside and sell.
There are clear winners with mostly losers in December …
Think about it; the biggest problem the cell and gene therapy sector has … 99% of them have no earnings! If rates are higher for longer, that means that sector companies will continue to struggle or be unable to raise capital and therefore be subject to debt servicing firms!
I seem to be asking a question followed by a question …
- Do we need to brace ourself for more economics and their down trending affect?
- Is this market STILL “bubblicious” my concerns are macroeconomic and valuation
Welcome to my world of defining the “grey’ in our universe!
- The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
- I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.
